Understanding how HTLV-1 virus causes DNA damage and cancer
Official title: HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-10739813 · Data updated 2026-11-12
This study is looking at how the HTLV-1 virus causes DNA damage and can lead to adult T-cell leukemia/lymphoma (ATL), focusing on specific viral proteins that might help us find better ways to prevent or treat this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | November 14, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $189,828 |
| NIH project number | 5R21AI173635-02 |
| Project ID | NIH-10739813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals infected with HTLV-1, particularly those who may be at risk of developing ATL.
✕Less likely to help
Patients who are not infected with HTLV-1 or those who have already developed ATL may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the HTLV-1 virus leads to DNA damage and the development of adult T-cell leukemia/lymphoma (ATL). It focuses on the viral proteins Tax and HBZ, which play critical roles in viral replication and the induction of genomic instability. By studying how these proteins interact with cellular processes, the research aims to uncover the pathways that lead to ATL. Patients may benefit from insights that could lead to new therapeutic strategies for preventing or treating ATL.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention and treatment options for patients at risk of developing ATL.
How similar studies have gone: Previous research has shown that understanding viral mechanisms can lead to significant advancements in cancer treatment, suggesting potential success for this approach.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Snow, Andrew L — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Snow, Andrew L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.